Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...

The FDA has approved the Lumipulse Plasma Ratio test, a groundbreaking blood test for early dementia detection. This less invasive alternative to PET scans and spinal taps measures amyloid-related ...

The new Lumipulse device reduces the need for a PET scan or other invasive testing, the agency said. In a clinical study of 499 plasma samples from cognitively impaired adults, ...

(BUSINESS WIRE )--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company's Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in ...

The FDA has cleared Fujirebio Diagnostics' Lumipulse blood test, marking the first of its kind for Alzheimer's diagnosis. This test measures pTau217 and β-amyloid 1-42 proteins to detect amyloid ...

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only. H.U. Group Holdings Inc. and its wholly-owned subsidiary ...

It’s called the Lumipulse Plasma Ratio, and is for the early detection of amyloid plaques associated with Alzheimer’s disease in adult patients aged 55 years and older who are exhibiting signs ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...